Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma

This study is being done to answer the main question of: Do patients with colorectal cancer that cannot be removed by surgery, that is treated with two new immunotherapy drugs, botensilimab and balstilimab, live longer? Other important questions include: Is their quality of life better? Do their tumours slow in growth or possibly shrink in size? Are there markers in their tumour or blood that can predict whether they achieve any of these benefits? In addition, the study is done to confirm the safety of these immunotherapy drugs and to determine how long it takes for the body to metabolize them

Trial Details

NCT ID
NCT07152821
Phase
PHASE3
Sponsor
Canadian Cancer Trials Group
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • Best Supportive Care
  • Balstilimab
  • Botensilimab
Locations (sample)
  • Prince George, British Columbia, Canada|53.9166,-122.75301
  • Vancouver, British Columbia, Canada|49.24966,-123.11934
  • Kingston, Ontario, Canada|44.22976,-76.48098
  • Oshawa, Ontario, Canada|43.90012,-78.84957
  • Ottawa, Ontario, Canada|45.41117,-75.69812

Key Eligibility Criteria

  • Must have histologically confirmed colorectal adenocarcinoma that is not deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H).
  • Received and failed all prior available therapies, such that the standard of care for the patient would be best supportive care (BSC).
  • Must have an Eastern Cooperative Oncology Group (ECOG) performance status 0, or 1.
  • Must have presence of measurable or evaluable disease as defined by Response Evaluation Criteria in Solid Tumours (RECIST 1.1).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →